Blood lumican levels and bone fragility in postmenopausal women with osteoporosis
Looks at whether blood lumican reveals bone fragility in postmenopausal women.
Plain-language title generated from the registry record
Registry title: Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Key facts
- Where
- Küçükçekmece, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for postmenopausal women aged 45 or older who come to the Physical Medicine and Rehabilitation outpatient clinic for a routine bone density (DEXA) scan and osteoporosis blood tests.
- Age
- 45 years or older
- Sex
- Women only
- Disease stage
- Postmenopausal women having a routine osteoporosis check-up; no disease stage is asked for.
- Earlier treatment
- People currently taking medicines that strongly affect bone, such as bisphosphonates, denosumab, teriparatide or other anti-osteoporosis drugs, cannot join.
Main reasons for not taking part
- Women who have not yet gone through menopause
- Other causes of osteoporosis, such as cancer, advanced kidney failure, severe liver disease or significant hormone disorders
- Active infection or acute inflammatory disease
- Major surgery within the previous 6 months
- Nerve or muscle disorders that may significantly affect muscle function
Read by machine on 12 November 2026.
Where in Türkiye
- Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, TurkeyKüçükçekmece, TürkiyeContact: Dilek Ün Oğuzhanasiltürk, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kanuni Sultan Suleyman Training and Research Hospital
- Trial code
- NCT07677072
- Record updated
- 30 June 2026
- Original description
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.Read full original descriptionShow less
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Inclusion: Female sex; Age 45 years or older; Postmenopausal status; Attendance at the Physical Medicine and Rehabilitation outpatient clinic; Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation; Ability and willingness to provide written informed consent.
Exclusion: Major surgery within the previous 6 months; Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents; Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders); Active infection or acute inflammatory disease; Neurological or muscular disorders that may significantly affect muscle function; Premenopausal women; Inability to comply with study procedures and assessments; Refusal or inability to provide written informed consent.